The FDA has cleared MavriX Bio, a Penn startup company based on technology developed by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director’s Professor in Penn Medicine, to initiate a clinical trial of a gene therapy for Angelman syndrome, potentially the first one-time treatment for this severe neurological disorder. Read more here.